Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

18.66USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$18.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
345,506
52-wk High
$21.47
52-wk Low
$11.43

Chart for

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $2,710.77
Shares Outstanding(Mil.): 143.73
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): 40.51 178.44 32.31
EPS (TTM): 0.46 -- --
ROI: 26.89 -0.73 12.97
ROE: 91.05 -2.77 14.84

BRIEF-Halozyme Therapeutics Says CEO Helen Torley's 2017 Compensation Was $5.18 Mln ‍​

* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING‍​ Source text - https://bit.ly/2udFEM8 Further company coverage:

Mar 22 2018

BRIEF-Halozyme Reports Q4 Earnings Per Share $0.85

* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage:

Feb 20 2018

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

Jan 09 2018

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Halozyme reports Q3 EPS of $0.02

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S

Nov 07 2017

BRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex

* Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​

Oct 31 2017

Competitors

Earnings vs. Estimates